OUR FORMULATIONS PORTFOLIO

NanoAlum consists of nanoparticle rods of aluminum oxyhydroxide

AAHI developed NanoAlum using a top-down manufacturing approach starting with commercial Alum (Alhydrogel®)

NanoAlum enhances Th1-type adjuvant activity compared to Alum, can be sterile-filtered and is stable to freeze-thaw

NanoAlum Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

NanoAlum elicits an enhanced TH1 immune response from the clinical adjuvant Alhydrogel and may be favorable for vaccines in the fields of tuberculosis, pertussis, and malaria.

(Orr, 2019. NPJ Vaccines)

Aqueous nanosuspensions of TLR ligands (e.g. GLA-AF) suitable for intradermal delivery.

The manufacturing process of aqueous nanosuspensions is straightforward and the cost of goods is low.

GLA-AF Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

SLA-AF Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

3M-052-AF Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine

(Haynes, 2022. Nature Communications)

A Phase 1 trial of GLA-AF + VLP influenza antigen showed broadened responses to heterologous strains

(Carter, 2018. Science Advances)

GLA and SLA are synthetic hexa-acylated monophosphoryl lipid A molecules with established safety and activity profile from Phase 1/2 clinical testing.

GLA and SLA were designed as synthetic analogues to the hexa-acylated component of the naturally derived MPL®

GLA and SLA are highly pure defined compounds designed for optimal TLR4 receptor binding, enabling substantially lower clinical dose compared to MPL®. In a squalene emulsion, they can also be lyophilized for single vial thermostable presentation or can be spray dried for thermostable nasal dry powder delivery.

GLA-SE Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

SLA-SE Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

GLA-SE enhances malaria antigen-specific antibodies and circulating Tfh in humans

(Hill, 2019. J Exp Med.)

SLA-SE induces Th1 immune responses in mice and humans immunized with a recombinant Leishmania vaccine antigen

(Carter, 2016. Clin Transl Immunology)

3M-052 (TLR7/8) is synthetic lipidated imidazoquinoline.

Developed by 3M and licensed to AAHI for specific indications.

3M-052 formulations developed by AAHI elicit exceptional response durability with strong Th1 bias in NHPs.

3M-052-SE Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

3M-052-Alum Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

3M-052-AF Adjuvant Portfolio 

Vaccine Adjuvant Compendium, NIH

3M-052-SE increases SARS-CoV-2 antibody magnitude and durability in infant non-human primates

(Permar, 2021. Sci Immunol.)

3M-052 formulations combined with an influenza antigen elicit protective efficacy in mouse and ferret challenge models

(Carter, Fox, 2017. Sci Rep.)

QS-21 is a saponin derived from Quillaja Saponaria associated with inflammasome activation.

cGMP QS-21 is obtained by AAHI from bark extract at high yield and high purity using a novel purification process.

AAHI’s QS-21 has been formulated in liposomes with GLA and tested in Phase 1 clinical trials.

GLA-LSQ Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

SLA-LSQ Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

An adjuvanted pregnancy-associated malaria vaccine candidate proved safe and immunogenic in a phase 1 clinical trial.

(Nielsen, 2019. Clin Infect Dis.)

A chromatographic process for p`urifying QS-21 from Quillaja Saponaria bark extract with high purity and yield.

(Qi, 2021. J Chromatogr A.)

GLA-3M-052-LS is a dual TLR ligand liposome adjuvant.

GLA-3M-052-LS was developed by AAHI in collaboration with 3M and the University of Virginia using an amebiasis vaccine candidate as a proof-of-concept.

This dual agonist develops a strong mucosal immune response as well as a Th1 type systemic response.

GLA-3M-052-LS Adjuvant Portfolio

Vaccine Adjuvant Compendium, NIH

An adjuvanted-protein COVID-19 vaccine candidate induced neutralizing antibodies in mice and protected from lethal challenge.

(Petri, 2021. Nature)

Intranasal administration of dual-agonist adjuvanted amebiasis vaccine candidate elicits robust mucosal and systemic protective immune response in mice

(Fox, 2018. NPJ Vaccines)